Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Depreciation & Amortization (CF) (2016 - 2019)

Syndax Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 5 years, most recently at -$176000.0 for Q3 2019.

  • Quarterly results put Depreciation & Amortization (CF) at -$176000.0 for Q3 2019, down 21.38% from a year ago — trailing twelve months through Jun 2020 was -$176000.0 (up 67.94% YoY), and the annual figure for FY2025 was $6.0 million, down 25.0%.
  • Depreciation & Amortization (CF) for Q3 2019 was -$176000.0 at Syndax Pharmaceuticals, up from -$224000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for SNDX hit a ceiling of $190000.0 in Q3 2015 and a floor of -$224000.0 in Q2 2019.
  • Median Depreciation & Amortization (CF) over the past 5 years was $4000.0 (2016), compared with a mean of -$12266.7.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 1725.0% in 2017 and later plummeted 1133.33% in 2018.
  • Syndax Pharmaceuticals' Depreciation & Amortization (CF) stood at $190000.0 in 2015, then plummeted by 136.32% to -$69000.0 in 2016, then soared by 323.19% to $154000.0 in 2017, then tumbled by 194.16% to -$145000.0 in 2018, then fell by 21.38% to -$176000.0 in 2019.
  • The last three reported values for Depreciation & Amortization (CF) were -$176000.0 (Q3 2019), -$224000.0 (Q2 2019), and -$180000.0 (Q1 2019) per Business Quant data.